Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: marc ultra who wrote (1811)	3/5/1999 10:58:00 AM
From: Mama Bear	Read Replies (1) \| Respond to of 2135

"The ENMD press release could not be clearer " Since it was not clear to everyone, the above statement can't be true. Barb

To: marc ultra who wrote (1811)	3/18/1999 11:46:00 PM
From: marc ultra	Read Replies (1) \| Respond to of 2135

From AACR Use of ENMD human AS in mice 315 Recombinant human AngiostatinTM protein expressed in Pichia pastoris inhibits B16BL6 melanoma in an experimental metastasis model. Fogler, W.E., Liang, H., Zhou, X.H., Lu, M., Madsen, J.W., Chang, A., Dey, C., Plum, S., Amelink, H., Nelson, B., Fortier, A.H., and Sim, B.K.L. EntreMed, Inc., 9610 Medical Center Dr. Rockville, MD 20850. Angiostatin has been shown to inhibit primary tumor growth in a number of murine models. This potent anti-angiogenic has also been shown to inhibit metastatic disease following removal of the primary Lewis Lung (LLC-LM) tumors in mice. We tested two different Pichia pastoris clones expressing human AngiostatinTM protein in an experimental metastasis model using the B16BL6 melanoma. Mice were inoculated intravenously with B16BL6 melanoma. AngiostatinTM protein therapy was initiated 3 days after tumor inoculation at 1.5 mg/kg every 12 hr for 11 consecutive days. On day 14 all mice were sacrificed, lungs were removed, fixed in formalin, and surface metastases were counted with a dissecting microscope. In five separate experiments, lung metastases were inhibited by 60-80% in mice treated with AngiostatinTM protein from either clone. Dose escalation studies are underway. These data are the first to show efficacy of recombinant AngiostatinTM protein in an experimental model of metastasis.